Docket No.

202617US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Man S. CO, et al.

SERIAL NO:

09/763,129

GAU:

1644

FILED:

May 16, 2001

EXAMINER: Gambel, P.

ANTITHROMBOTIC AGENT AND HUMANIZED ANTI-VON WILLEBRAND FACTOR MONOCLONAL **ANTIBODY**

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

MISSIONER FOR PATENTS TRADENEXANDRIA, VIRGINIA 22313

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- ☐ A check or credit card payment form is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check or credit card payment is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

OBLON, SPIVAK, McCLELLAND, MAIER & NEUSTADT, P.C.

Stephen G. Baxter

Registration No. 32,884

Tel. (703) 413-3000 Vincent K. Shier, Ph.D. Fax. (703) 413-2220 Registration No. 50,552

04/0G/2004 JEALINAN 00000118 09763129

(OSMMN 05/03)

Customer Number

02 FC:1806

180.00 OP

Form PTO 1449	U.S. DEPARTMENT OF COMMERCE			ATTY DOCKET NO.	SERIAL NO.				
(Modified)		PATENT AND TRAC	EMARK OFFICE	202617US0PCT	09/763,129				
SIPA				APPLICANT					
O LISTOF	REFER	RENCES CITED BY AP	PLICANT	Man S. CO, et al.					
O LISTOF REFERENCES CITED BY APPLICANT			FILING DATE		GROUP				
			May 16, 2001	1644					
	¥/			U.S. PATENT DOCUMENTS					
INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB CLASS	FILING DATE IF APPROPRIATE		
	AA				·				
	AB								
	AC								
	AD								
	AE								
	AF								
	AG								
	АН								
	Al								
	AJ								
	AK								
	AL								
	AM								
	AN								
			FC	REIGN PATENT DOCUMENTS					
		DOCUMENT DATE COUNTRY			TRANSLATION YES NO				
	AO								
	AP								
	AQ								
	AR								
	AS								
	AT								
	AU					ļ			
	AV								
		OTHER R	EFERENCES	(Including Author, Title, Date, Pertin	ent Pages, e	etc.)			
	AW	A. MANHEIMER-LOR ASSOCIATED IDIOT	Y, et al., "MOI YPE", J. Exp. I	ECULAR CHARACTERISTICS OF AN Med., Vol. 174, December 1991, pp. 16	NTIBODIES I 39-1652	BEARING A	AN ANTI-DNA-		
"	AX								
	AY								
	AZ				Add	litional Ref	ferences sheet(s) attached		
Examiner					Date Co	Date Considered			
*Examiner: I	nitial if r	reference is considered of considered. Include of	, whether or ne	ot citation is in conformance with MPEF m with next communication to applican	e 609; Draw l t.	ine throug	n citation if not in		

Docket No.

202617US0PCT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF:

Man S. CO, et al.

SERIAL NO: 09/763,129

GAU:

FILED:

May 16, 2002

EXAMINER:

FOR:

ANTITHROMBOTIC AGENT AND HUMANIZED ANTI-VON WILLEBRAND FACTOR MONOCLONAL

ANTIBODY

INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97

ASSISTANT COMMISSIONER FOR PATENTS WASHINGTON, D.C. 20231

Applicant(s) wish to disclose the following information.

REFERENCES

- The applicant(s) wish to make of record the references listed on the attached form PTO-1449. Copies of the listed references are attached, where required, as are either statements of relevancy or any readily available English translations of pertinent portions of any non-English language references.
- A check is attached in the amount required under 37 CFR §1.17(p).

RELATED CASES

- Attached is a list of applicant's pending application(s) or issued patent(s) which may be related to the present application. A copy of the patent(s), together with a copy of the claims and drawings of the pending application(s) is attached along with PTO 1449.
- A check is attached in the amount required under 37 CFR §1.17(p).

CERTIFICATION

- ☐ Each item of information contained in this information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- □ No item of information contained in this information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to the knowledge of the undersigned, having made reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this statement.

DEPOSIT ACCOUNT

Please charge any additional fees for the papers being filed herewith and for which no check is enclosed herewith, or credit any overpayment to deposit account number 15-0030. A duplicate copy of this sheet is enclosed.

Respectfully submitted,

SPIVAK, McCLELLAND, NEUSTADT, P.C.

Norman F. Oblo

Registration No.

Surinder Sachar

Registration No. 34,423

22850

Tel. (703) 413-3000 Fax. (703) 413-2220 (OSMMN 03/02)

Form PTO 1449		U.S. DEPARTMENT OF	COMMERCE	ATTY DOCKET NO.	SERIAL NO.				
(Modified)		PATENT AND TRADE	WARK OFFICE	202617US0PCT	09/763,129				
				APPLICANT					
LIST OF REFERENCES CITED BY APPLICANT				Man S. CO, et al.					
				FILING DATE		GROUP			
				May 16, 2002					
				J.S. PATENT DOCUMENTS					
EXAMINER		DOCUMENT	DATE	NAME	CLASS	SUB	FILING DATE		
INITIAL		NUMBER	DATE	NAME	CLASS	CLASS	IF APPROPRIATE		
	AA								
	AB	·							
	AC								
	AD		,	· .					
	AE						,		
	AF					9			
	AG		· · · · · · · · · · · · · · · · · · ·				~		
	AH	·			 		On		
	Al	<u> </u>			-				
	AJ		····		-				
-				·					
	AK		· <u>-</u>	·		 	·		
	AL			· · · · · · · · · · · · · · · · · · ·	1				
	AM			<u> </u>					
l	AN				Т.	L			
•			FO	REIGN PATENT DOCUMENTS					
	٠	DOCUMENT NUMBER	DATE	COUNTRY	TRANSLATION				
		110111211				YES	S NO		
	AO						·		
-	AP						· · · · · ·		
	AQ			· · · · · · · · · · · · · · · · · · ·					
	AR					·			
	AS								
	AT	· · · · · · · · · · · · · · · · · · ·		· · · · · · · · · · · · · · · · · · ·		:			
	AU								
· ·	AV								
		OTHER REFI	ERENCES (I	ncluding Author, Title, Date, Pertiner	nt Pages, et	tc.)			
	$\overline{}$	YAMAMOTO et al.: "Ant	i-von willebra	nd factor antibody AJvW-2 specifically	inhibits arte	rial but no	t venous thrombosis in the		
	AW	hamster*		rt 1-2, page 677, Abstract 172A					
	7		thrombotic e	ffects and bleeding risk of AJvW-2, a n	nonoclonal a	antibody ag	gainst human von		
·	AX	willebrand factor*		LOGY, vol. 122, pages 165-171					
	7	POLETTI et al.: "Prevention of arterial thrombosis using a novel heparin with enhanced antiplatelet activity and reduce							
	AY	anticoagulant activity* JOURNAL OF VASCULA 1997	R SURGER	Y, vol. 26, no. 3, pages 366-372					
	AZ				Addi	tional Refe	erences sheet(s) attached		
Examiner					Date Considered				
		•			Date Con	isiaerea	•		
				citation is in conformance with MPEP 6 with next communication to applicant.	<u> </u>		citation if not in		